X‐PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced‐energy diet. Early response to treatment predicts weight maintenance
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aim: To determine the effect of two different levels of energy deficit on weight loss in obese patients treated with orlistat. Methods: Patients (n = 430) were randomized in a 1‐year, multicentre, open‐label, parallel group study conducted at 23 hospital centres and university medical departments worldwide. Obese outpatients (body mass index 30–43 kg/m 2 ) aged 18–70 years with a body weight of ≥90 kg and a waist circumference of ≥88 cm (women) or ≥102 cm (men) were treated with orlistat 120 mg three times daily plus a diet that provided an energy deficit of either 500 or 1000 kcal/day for 1 year. Orlistat treatment was discontinued in patients who did not achieve ≥5% weight loss after assessment at 3 and 6 months. The primary outcome measure was change in body weight from baseline at week 52. Results: Reported mean difference in energy intake between the two groups (500–1000 kcal/day deficit) at weeks 24 and 52 was actually 111 and 95 kcal/day respectively. Of the 430 patients involved in the study, 295 achieved ≥5% weight loss at both 3 and 6 months. In this population, at week 52, weight loss from baseline was similar for patients randomized to either the 500 or the 1000 kcal/day deficit diet (−11.4 kg vs. −11.8 kg, respectively; p = 0.778). After 12 months of treatment with orlistat, 84% (n = 118/141) and 85% (n = 131/154) of patients in the 500 and 1000 kcal/day deficit groups, respectively, achieved ≥5% weight loss, and 50% (n = 70/141) and 53% (n = 82/154) of patients, respectively, achieved ≥10% weight loss. Patients in both the diet treatment groups showed similar significant improvements in blood pressure, lipid levels and waist circumference at week 52. Conclusions: Treatment with orlistat was associated with a clinically beneficial weight loss, irrespective of the prescribed dietary energy restriction (−500 or −1000 kcal/day). Patients who achieved ≥5% weight loss at 3 months achieved long‐term, clinically beneficial weight loss with orlistat plus either diet. Therefore, identifying patients who lose at least 5% weight after 3 months and who maintain this weight loss up to 6 months is a valuable treatment algorithm to select patients who will benefit most from orlistat treatment in combination with diet.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476
Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1033 · Cited by 314
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin
Miles, J. M., Leiter, L., Hollander, P., Wadden, T., Anderson, J. W., Doyle, M., Foreyt, J., Aronne, L., & Klein, S. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1123 · Cited by 286
Reduction of body weight and co‐morbidities by orlistat: The XXL – Primary Health Care Trial
Wirth, A. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00428.x · Cited by 39
Cited by
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Self-citationFuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
Salas-Salvadó, J., Rubio, M. A., Barbany, M., & Moreno, B. (2007) · Medicina Clínica · doi:10.1016/s0025-7753(07)72531-9 · Cited by 571
Orlistat-Associated Adverse Effects and Drug Interactions: A Critical Review
Filippatos, T. D., Derdemezis, C. S., Gazi, I. F., Nakou, E. S., Mikhailidis, D. P., & Elisaf, M. S. (2008) · Drug Safety · doi:10.2165/00002018-200831010-00005 · Cited by 434
Metadata
- Authors
- Toplak, H., Ziegler, O., Keller, U., Hamann, A., Godin, C., Wittert, G., Zanella, M. ‐., Zúñiga‐Guajardo, S., & Van Gaal, L.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2005-04-06
- Volume
- 7
- Issue
- 6
- Pages
- 699-708
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2053986195
- Cited by
- 86
- References
- 6
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: X‐PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced‐energy diet. Early response to treatment predicts weight maintenance. https://app.cochat.ai/papers/10.1111/j.1463-1326.2005.00483.x
- The paper
- Toplak, H., Ziegler, O., Keller, U., Hamann, A., Godin, C., Wittert, G., Zanella, M. ‐., Zúñiga‐Guajardo, S., & Van Gaal, L. (2005). X‐PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced‐energy diet. Early response to treatment predicts weight maintenance. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2005.00483.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.